B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

Overview of attention for article published in ImmunoTargets and Therapy, January 2014

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase

Article in Journal of Clinical Pharmacy and Therapeutics (March 2022)

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia

Article in Expert Opinion on Investigational Drugs (October 2017)

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Article in Current Oncology Reports (July 2017)